Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta-Analysis - PubMed
6 hours ago
- #severe asthma
- #biologics switch
- #clinical efficacy
- Biologics switching in severe asthma most commonly involves switching from mepolizumab to benralizumab or from omalizumab to mepolizumab/benralizumab.
- The primary reason for switching biologics is suboptimal asthma control, accounting for 77% of cases.
- Switching biologics significantly reduces asthma exacerbations, emergency visits, hospitalizations, and oral corticosteroid use.
- Asthma control improves post-switch, with notable increases in ACT scores and decreases in ACQ scores.
- Lung function (FEV1) improves, and type 2 inflammation biomarkers (e.g., eosinophils, IgE, FeNO) decrease after switching.
- Switching decisions should consider clinical remission goals, comorbidities, side effects, cost, and patient preferences.